Pathophysiology and classification of pseudomyxoma peritonei

被引:1
作者
Bignell, Mark [1 ]
Carr, Norman J. [1 ,3 ]
Mohamed, Faheez [1 ,2 ]
机构
[1] Peritoneal Malignancy Inst, Basingstoke, Hants, England
[2] North Hamsphire Hosp, Aldermaston Rd, Basingstoke RG24 9NA, Hants, England
[3] Univ Southampton, Cellular Pathol, Southampton, Hants, England
关键词
appendiceal mucinous neoplasm; cytoreductive surgery; HIPEC; oncogenes; pseudomyxoma peritonei (PMP); tumour markers;
D O I
10.1515/pap-2016-0008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The term pseudomyxoma peritonei (PMP) was first described in 1884 and there has been much debate since then over the term. A recent consensus of world experts agreed that PMP should be thought of as a clinical entity characterised by the presence of mucinous ascites, omental cake, peritoneal implants and possibly ovarian involvement. It generally originates from mucinous appendiceal tumours. Content: This review details the clinical presentation of this unusual condition, presents the new classification system and how this relates to outcome. The pathophysiology of this disease is also explored with a special reference to the relationship of the disease to tumour markers. Summary: A classification system has been agreed upon by the leading experts in PMP which is now divided into low and high grade mucinous carcinomatosis peritonei. This distinction correlates with clinical outcome as does the presence of raised tumour markers preoperatively. Outlook: Research needs to be focused on understanding the factors associated with poor prognosis through well designed multi-centred prospective studies. This will allow us to identify patients with bad tumour biology so that targeted treatment based on likely prognosis may then become a reality.
引用
收藏
页码:3 / 13
页数:11
相关论文
共 63 条
  • [1] Ahnen DJ, 1998, CANCER RES, V58, P1149
  • [2] Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin
    Alakus, Hakan
    Babicky, Michele L.
    Ghosh, Pradipta
    Yost, Shawn
    Jepsen, Kristen
    Dai, Yang
    Arias, Angelo
    Samuels, Michael L.
    Mose, Evangeline S.
    Schwab, Richard B.
    Peterson, Michael R.
    Lowy, Andrew M.
    Frazer, Kelly A.
    Harismendy, Olivier
    [J]. GENOME MEDICINE, 2014, 6
  • [3] Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence
    Alexander-Sefre, F
    Chandrakumaran, K
    Banerjee, S
    Sexton, R
    Thomas, JM
    Cecil, T
    Moran, B
    [J]. COLORECTAL DISEASE, 2005, 7 (04) : 382 - 386
  • [4] Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study
    Andreyev, HJN
    Norman, AR
    Cunningham, D
    Oates, J
    Dix, BR
    Iacopetta, BJ
    Young, J
    Walsh, T
    Ward, R
    Hawkins, N
    Beranek, M
    Jandik, P
    Benamouzig, R
    Jullian, E
    Laurent-Puig, P
    Olschwang, S
    Muller, O
    Hoffmann, I
    Rabes, HM
    Zietz, C
    Troungos, C
    Valavanis, C
    Yuen, ST
    Ho, JWC
    Croke, CT
    O'Donoghue, DP
    Giaretti, W
    Rapallo, A
    Russo, A
    Bazan, V
    Tanaka, M
    Omura, K
    Azuma, T
    Ohkusa, T
    Fujimori, T
    Ono, Y
    Pauly, M
    Faber, C
    Glaesener, R
    de Goeij, AFPM
    Arends, JW
    Andersen, SN
    Lövig, T
    Breivik, J
    Gaudernack, G
    Clausen, OPF
    De Angelis, P
    Meling, GI
    Rognum, TO
    Smith, R
    [J]. BRITISH JOURNAL OF CANCER, 2001, 85 (05) : 692 - 696
  • [5] Pseudomyxoma peritonei: Clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)
    Baratti, Dario
    Kusamura, Shigeki
    Nonaka, Daisuke
    Langer, Martin
    Andreola, Salvatore
    Favaro, Miriam
    Gavazzi, Cecilia
    Laterza, Barbara
    Deraco, Marcello
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (02) : 526 - 534
  • [6] Pseudomyxoma Peritonei Biological Features Are the Dominant Prognostic Determinants After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy
    Baratti, Dario
    Kusamura, Shigeki
    Nonaka, Daisuke
    Cabras, Antonello Domenico
    Laterza, Barbara
    Deraco, Marcello
    [J]. ANNALS OF SURGERY, 2009, 249 (02) : 243 - 249
  • [7] PROGNOSTIC VALUE OF P53 OVEREXPRESSION AND C-KI-RAS GENE-MUTATIONS IN COLORECTAL-CANCER
    BELL, SM
    SCOTT, N
    CROSS, D
    SAGAR, P
    LEWIS, FA
    BLAIR, GE
    TAYLOR, GR
    DIXON, MF
    QUIRKE, P
    [J]. GASTROENTEROLOGY, 1993, 104 (01) : 57 - 64
  • [8] A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei
    Bibi, R.
    Pranesh, N.
    Saunders, M. P.
    Wilson, M. S.
    O'Dwyer, S. T.
    Stern, P. L.
    Renehan, A. G.
    [J]. BRITISH JOURNAL OF CANCER, 2006, 95 (09) : 1258 - 1264
  • [9] Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
    Bokemeyer, C.
    Bondarenko, I.
    Hartmann, J. T.
    de Braud, F.
    Schuch, G.
    Zubel, A.
    Celik, I.
    Schlichting, M.
    Koralewski, P.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (07) : 1535 - 1546
  • [10] Pseudomyxoma peritonei of appendiceal origin: A clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review
    Bradley, RF
    Stewart, JH
    Russell, GB
    Levine, EA
    Geisinger, KR
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2006, 30 (05) : 551 - 559